Cyclophosphamide

Cyclophosphamide

Error creating thumbnail: File missing
Clinical data
Pregnancy category	AU: D US: D (Evidence of risk)
Routes of administration	Oral, intravenous
ATC code	L01AA01 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	>75% (oral)
Protein binding	>60%
Metabolism	Hepatic
Elimination half-life	3-12 hours
Excretion	Renal
Identifiers
IUPAC name N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
CAS Number	50-18-0
PubChem CID	2907
DrugBank	APRD00408
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C7H15Cl2N2O2P
Molar mass	261.085 g/mol
3D model (JSmol)	Interactive image
Melting point	2 °C (35.6 °F)
SMILES C1CNP(=O)(OC1)N(CCCl)CCCl

WikiDoc Resources for Cyclophosphamide
Articles
Most recent articles on Cyclophosphamide Most cited articles on Cyclophosphamide Review articles on Cyclophosphamide Articles on Cyclophosphamide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cyclophosphamide Images of Cyclophosphamide Photos of Cyclophosphamide Podcasts & MP3s on Cyclophosphamide Videos on Cyclophosphamide
Evidence Based Medicine
Cochrane Collaboration on Cyclophosphamide Bandolier on Cyclophosphamide TRIP on Cyclophosphamide
Clinical Trials
Ongoing Trials on Cyclophosphamide at Clinical Trials.gov Trial results on Cyclophosphamide Clinical Trials on Cyclophosphamide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cyclophosphamide NICE Guidance on Cyclophosphamide NHS PRODIGY Guidance FDA on Cyclophosphamide CDC on Cyclophosphamide
Books
Books on Cyclophosphamide
News
Cyclophosphamide in the news Be alerted to news on Cyclophosphamide News trends on Cyclophosphamide
Commentary
Blogs on Cyclophosphamide
Definitions
Definitions of Cyclophosphamide
Patient Resources / Community
Patient resources on Cyclophosphamide Discussion groups on Cyclophosphamide Patient Handouts on Cyclophosphamide Directions to Hospitals Treating Cyclophosphamide Risk calculators and risk factors for Cyclophosphamide
Healthcare Provider Resources
Symptoms of Cyclophosphamide Causes & Risk Factors for Cyclophosphamide Diagnostic studies for Cyclophosphamide Treatment of Cyclophosphamide
Continuing Medical Education (CME)
CME Programs on Cyclophosphamide
International
Cyclophosphamide en Espanol Cyclophosphamide en Francais
Business
Cyclophosphamide in the Marketplace Patents on Cyclophosphamide
Experimental / Informatics
List of terms related to Cyclophosphamide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Cyclophosphamide (the generic name for Cytoxan, Neosar), also known as cytophosphane, is a nitrogen mustard alkylating agent, used to treat various types of cancer and some autoimmune disorders. It is a "prodrug"; it is converted in the liver to active forms that have chemotherapeutic activity.

Uses

The main use of cyclophosphamide is together with other chemotherapy agents in the treatment of lymphomas, some forms of leukemia and some solid tumors. It is a chemotherapy drug that works by slowing or stopping cell growth. It also works by decreasing the immune system's response to various diseases.

In addition, its use is becoming more common in autoimmune diseases where disease-modifying antirheumatic drugs (DMARDs) have been ineffective. Systemic lupus erythematosus (SLE) with severe lupus nephritis, for example, may respond to pulsed cyclophosphamide. However in 2005, standard treatment for lupus nephritis changed to MMF from cyclophosphamide.

It is also used to treat Minimal Change Disease and rheumatoid arthritis. It is still used for Wegener's granulomatosis. The trade name is Endoxan.

Pharmacokinetics/Pharmacodynamics

Cyclophosphamide is converted by mixed function oxidase enzymes in the liver to active metabolites. The main active metabolite is 4-hydroxycyclophosphamide. 4-hydroxycyclophosphamide exists in equilibrium with its tautomer, aldophosphamide. Most of the aldophosphamide is oxidised by the enzyme aldehyde dehydrogenase (ALDH) to make carboxyphosphamide. A small proportion of aldophosphamide is converted into phosphoramide mustard and acrolein. Acrolein is toxic to the bladder epithelium and can lead to hemorrhagic cystitis. This can be prevented through the use of aggressive hydration and/or Mesna.

Recent clinical studies have shown that cyclophosphamide induce beneficial immunomodulatory effects in the context of adoptive immunotherapy. Although the mechanisms underlying these effects are not fully understood, several mechanisms have been suggested based on potential modulation of the host environment, including:

1. Elimination of T regulatory cells (CD4+CD25+ T cells) in naive and tumor-bearing hosts
2. Induction of T cell growth factors such as type I IFNs, and/or
3. Enhanced grafting of adoptively transferred tumor-reactive effector T cells by the creation of an immunologic space niche.

Thus, cyclophosphamide pre-conditioning of recipient hosts (for donor T cells) has been used to enhance immunity in naïve hosts, and to enhance adoptive T cell immunotherapy regimens as well as active vaccination strategies, inducing objective anti-tumor immunity.

Mode of action

The main effect of cyclophosphamide is due to its metabolite phosphoramide mustard. This metabolite is only formed in cells which have low levels of ALDH.

Phosphoramide mustard forms DNA crosslinks between (interstrand crosslinkages) and within (intrastrand crosslinkages) DNA strands at guanine N-7 positions. This leads to cell death.

Cyclophosphamide has relatively little typical chemotherapy toxicity as ALDHs are present in relatively large concentrations in bone marrow stem cells, liver and intestinal epithelium. ALDHs protect these actively proliferating tissues against toxic effects phosphoramide mustard and acrolein by converting aldophosphamide to carboxyphosphamide that does not give rise to the toxic metabolites (phosphoramide mustard and acrolein).

Side-effects

Many people taking cyclophosphamide do not have serious side effects. Side-effects include chemotherapy-induced nausea and vomiting (CINV), bone marrow suppression, stomach ache, diarrhea, darkening of the skin/nails, alopecia (hair loss) and lethargy. Hemorrhagic cystitis is a frequent complication, but this is prevented by adequate fluid intake and Mesna (sodium 2-mercaptoethane sulfonate). Mesna is a sulfhydryl donor and binds acrolein.

Cyclophosphamide is itself carcinogenic, potentially causing transitional cell carcinoma of the bladder as a long-term complication. It can lower the body's ability to fight an infection. It can cause temporary or (rarely) permanent sterility. Although it is used to treat cancer, it may increase the risk of developing another form of cancer, sometimes months to years after treatment.

Other (serious) side effects include:

• pink/bloody urine,
• unusual decrease in the amount of urine,
• mouth sores,
• unusual tiredness or weakness,
• joint pain,
• easy bruising/bleeding,
• stopping of menstrual periods,
• existing wounds that are slow healing.

History

Cyclophosphamide and the related nitrogen mustard-derived alkylating agent ifosfamide were developed by Norbert Brock and ASTA (now Baxter Oncology). Brock and his team synthesised and screened more than 1,000 candidate oxazaphosphorine compounds. They converted the base nitrogen mustard into a non-toxic "transport form". This transport form was a pro-drug, subsequently actively transported into the cancer cells. Once in the cells, the pro-drug was enzymatically converted into the active, toxic form. The first clinical trials were published at the end of the 1950s.

References

Template:WikiDoc Sources